Corcept Therapeutics vs Royalty Pharma: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Corcept Therapeutics Incorporated (CORT)

Q3 202627 Jul – 29 Sep 2026

▲4

Corcept's earnings blowout and raised outlook lift the stock

Q2 results smash expectations, guidance raised Corcept reported second-quarter revenue of $256.1 million, up 31.7% from a year earlier and 21.6% above what analysts expected, with profit also beating. Management raised its 2026 revenue forecast to $1.1-$1.2 billion. A company beating expectations and raising its outlook makes investors pay more for the stock.
This is the core new event driving the stock: a big earnings beat plus a raised full-year forecast.
New ovarian cancer drug Lifyorli starts selling Lifyorli, approved in March 2026 for platinum-resistant ovarian cancer, brought in $47.6 million in its first quarter on the market. A brand-new product generating real sales means the company is no longer relying on one drug, which supports a higher value for the stock.
It shows a second revenue source actually selling, a new fact that supports the bull case.
Korlym keeps growing; second approval decision due Dec. 17 Korlym, the Cushing's syndrome drug, sold $373.5 million in the first half, up 6.2%. Corcept also resubmitted its application for relacorilant in hypercortisolism, which the FDA accepted with a decision expected by December 17, 2026 — a possible second use for its key drug.
Ongoing Korlym growth plus a near-term FDA decision are the fundamental forces behind the stock.
Analysts sharply raise profit forecasts Over the past 60 days, the average analyst estimate for 2026 earnings per share jumped from 58 cents to $2.02, and for 2027 from $2.27 to $3.44. When expected profits rise this fast, the stock usually re-rates higher because it looks cheaper relative to those profits.
Rising earnings estimates explain why the stock's valuation has moved up, not just the headline beat.

August 202627 Jul – 29 Sep 2026

▲4

Corcept's earnings blowout and raised outlook lift the stock

Q2 results smash expectations, guidance raised Corcept reported second-quarter revenue of $256.1 million, up 31.7% from a year earlier and 21.6% above what analysts expected, with profit also beating. Management raised its 2026 revenue forecast to $1.1-$1.2 billion. A company beating expectations and raising its outlook makes investors pay more for the stock.
This is the core new event driving the stock: a big earnings beat plus a raised full-year forecast.
New ovarian cancer drug Lifyorli starts selling Lifyorli, approved in March 2026 for platinum-resistant ovarian cancer, brought in $47.6 million in its first quarter on the market. A brand-new product generating real sales means the company is no longer relying on one drug, which supports a higher value for the stock.
It shows a second revenue source actually selling, a new fact that supports the bull case.
Korlym keeps growing; second approval decision due Dec. 17 Korlym, the Cushing's syndrome drug, sold $373.5 million in the first half, up 6.2%. Corcept also resubmitted its application for relacorilant in hypercortisolism, which the FDA accepted with a decision expected by December 17, 2026 — a possible second use for its key drug.
Ongoing Korlym growth plus a near-term FDA decision are the fundamental forces behind the stock.
Analysts sharply raise profit forecasts Over the past 60 days, the average analyst estimate for 2026 earnings per share jumped from 58 cents to $2.02, and for 2027 from $2.27 to $3.44. When expected profits rise this fast, the stock usually re-rates higher because it looks cheaper relative to those profits.
Rising earnings estimates explain why the stock's valuation has moved up, not just the headline beat.

Latest27 Jul – 29 Sep 2026

▲4

Corcept's earnings blowout and raised outlook lift the stock

Q2 results smash expectations, guidance raised Corcept reported second-quarter revenue of $256.1 million, up 31.7% from a year earlier and 21.6% above what analysts expected, with profit also beating. Management raised its 2026 revenue forecast to $1.1-$1.2 billion. A company beating expectations and raising its outlook makes investors pay more for the stock.
This is the core new event driving the stock: a big earnings beat plus a raised full-year forecast.
New ovarian cancer drug Lifyorli starts selling Lifyorli, approved in March 2026 for platinum-resistant ovarian cancer, brought in $47.6 million in its first quarter on the market. A brand-new product generating real sales means the company is no longer relying on one drug, which supports a higher value for the stock.
It shows a second revenue source actually selling, a new fact that supports the bull case.
Korlym keeps growing; second approval decision due Dec. 17 Korlym, the Cushing's syndrome drug, sold $373.5 million in the first half, up 6.2%. Corcept also resubmitted its application for relacorilant in hypercortisolism, which the FDA accepted with a decision expected by December 17, 2026 — a possible second use for its key drug.
Ongoing Korlym growth plus a near-term FDA decision are the fundamental forces behind the stock.
Analysts sharply raise profit forecasts Over the past 60 days, the average analyst estimate for 2026 earnings per share jumped from 58 cents to $2.02, and for 2027 from $2.27 to $3.44. When expected profits rise this fast, the stock usually re-rates higher because it looks cheaper relative to those profits.
Rising earnings estimates explain why the stock's valuation has moved up, not just the headline beat.

Royalty Pharma Plc (RPRX)

Q3 202629 Jun – 13 Aug 2026

▲4

Royalty Pharma Raises Guidance Again, Adds AstraZeneca Royalty

Q2 beat and second guidance raise Royalty Pharma beat expectations and raised its 2026 outlook for the second quarter in a row, now guiding to $3.4–3.5 billion in portfolio receipts. Strong sales of Tremfya, Voranigo, Emdeltra and Evrysdi drove the beat, signaling its royalty base keeps growing.
This is the core new fundamental driver of the period and directly lifts future earnings expectations.
New AstraZeneca cliramitug royalty deal Royalty Pharma is paying up to $425 million for a 3–4% royalty on AstraZeneca's cliramitug, a Phase 3 heart drug for ATTR-CM. With peak sales seen at $3–5 billion, this adds a potential $110–190 million in annual royalty revenue later this decade.
This is a fresh capital deployment that expands the royalty portfolio and future cash flow.
Lupus drug litifilimab nears key data Royalty Pharma co-developed litifilimab with Biogen, and Phase 3 enrollment is complete with topline results due in the second half of 2026. Positive data would validate another late-stage pipeline asset and support future royalty growth.
It highlights a near-term clinical catalyst that could add a new royalty stream.
Stock hits 52-week high on earnings momentum RPRX touched $60.44 as investors reacted to 13% growth in first-quarter royalty receipts and the raised full-year outlook. The stock has gained 56% over the past year, reflecting growing confidence in the royalty model.
It shows the market is rewarding the company's consistent execution, reinforcing the positive trend.

July 202629 Jun – 13 Aug 2026

▲4

Royalty Pharma Raises Guidance Again, Adds AstraZeneca Royalty

Q2 beat and second guidance raise Royalty Pharma beat expectations and raised its 2026 outlook for the second quarter in a row, now guiding to $3.4–3.5 billion in portfolio receipts. Strong sales of Tremfya, Voranigo, Emdeltra and Evrysdi drove the beat, signaling its royalty base keeps growing.
This is the core new fundamental driver of the period and directly lifts future earnings expectations.
New AstraZeneca cliramitug royalty deal Royalty Pharma is paying up to $425 million for a 3–4% royalty on AstraZeneca's cliramitug, a Phase 3 heart drug for ATTR-CM. With peak sales seen at $3–5 billion, this adds a potential $110–190 million in annual royalty revenue later this decade.
This is a fresh capital deployment that expands the royalty portfolio and future cash flow.
Lupus drug litifilimab nears key data Royalty Pharma co-developed litifilimab with Biogen, and Phase 3 enrollment is complete with topline results due in the second half of 2026. Positive data would validate another late-stage pipeline asset and support future royalty growth.
It highlights a near-term clinical catalyst that could add a new royalty stream.
Stock hits 52-week high on earnings momentum RPRX touched $60.44 as investors reacted to 13% growth in first-quarter royalty receipts and the raised full-year outlook. The stock has gained 56% over the past year, reflecting growing confidence in the royalty model.
It shows the market is rewarding the company's consistent execution, reinforcing the positive trend.

Latest29 Jun – 13 Aug 2026

▲4

Royalty Pharma Raises Guidance Again, Adds AstraZeneca Royalty

Q2 beat and second guidance raise Royalty Pharma beat expectations and raised its 2026 outlook for the second quarter in a row, now guiding to $3.4–3.5 billion in portfolio receipts. Strong sales of Tremfya, Voranigo, Emdeltra and Evrysdi drove the beat, signaling its royalty base keeps growing.
This is the core new fundamental driver of the period and directly lifts future earnings expectations.
New AstraZeneca cliramitug royalty deal Royalty Pharma is paying up to $425 million for a 3–4% royalty on AstraZeneca's cliramitug, a Phase 3 heart drug for ATTR-CM. With peak sales seen at $3–5 billion, this adds a potential $110–190 million in annual royalty revenue later this decade.
This is a fresh capital deployment that expands the royalty portfolio and future cash flow.
Lupus drug litifilimab nears key data Royalty Pharma co-developed litifilimab with Biogen, and Phase 3 enrollment is complete with topline results due in the second half of 2026. Positive data would validate another late-stage pipeline asset and support future royalty growth.
It highlights a near-term clinical catalyst that could add a new royalty stream.
Stock hits 52-week high on earnings momentum RPRX touched $60.44 as investors reacted to 13% growth in first-quarter royalty receipts and the raised full-year outlook. The stock has gained 56% over the past year, reflecting growing confidence in the royalty model.
It shows the market is rewarding the company's consistent execution, reinforcing the positive trend.